Arcus Biosciences stock falls after pricing $250 million public offering By Investing.com
Update: 2025-10-31
Description
Arcus Biosciences, a clinical-stage biopharmaceutical company, announced a $250 million public offering, issuing 13.7 million new shares at $18.25 each. The offering is set to close on November 3rd, with underwriters having the option to buy an additional 2.055 million shares. The company's stock dropped nearly 9% due to dilution and the discounted share price. Investors are now watching how Arcus will use the funds and if they can deliver positive clinical trial results, as the company aims to bring new medicines to market.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
